EGFR and lung cancer: Preliminary results suggested that EGFR wild-type lung cancer cell H1650 and EGFR mutant lung cancer H1975 cells showed poor sensitivity to icotinib with IC50 values of >50 μM, and icotinib-triazole derivatives such as 3b, 3d, 3e, 3g, 3i, 3k, 3l, 3n, 3o and 3v all exhibited stronger killing effects on the above lung cancer cell lines than icotinib did.